Swedish Orphan Biovitrum AB (publ)

• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 Phase III 10 countries EFANESOCTOCOG ALFA
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Recruiting
  2022-500275-31-00 Phase III 14 countries EFANESOCTOCOG ALFA
• Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting
  2024-517812-31-00 Phase IV 8 countries EFANESOCTOCOG ALFA
• A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended
  2024-512066-33-00 Phase IV 4 countries EFANESOCTOCOG ALFA
• Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A Ended
  2023-505801-17-00 4 countries
• An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended
  2022-502921-16-00 Phase IV 10 countries EFMOROCTOCOG ALFA; EFTRENONACOG ALFA
• A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macro… Ended
  2024-516153-52-00 Phase II/III 3 countries EMAPALUMAB
• Study to evaluate Pegcetacoplan in patients with TA-TMA after hematopoietic stem cell transplantation Ended
  2023-510443-37-00 Phase II 4 countries

Showing 1–8 of 8 trials